AHR and cancer: In 2008, Hollingshead group [81] obtained an inflammatory state in MCF-7 breast and ECC-1 endocervical cancer cells, through the administration of IL-1β or phorbol 12-myristate 13-acetate (PMA), in combination with TCDD-induced activation of AhR.